GEN Exclusives

More »

GEN News Highlights

More »
Jan 31, 2008

SAFC Initiates Second Phase of a $600K Research Facility Expansion

  • SAFC has begun the second-phase of a $600,000 expansion of its solid-state services Pharmorphix research facility in Cambridge, U.K. The building will include 7,500 sq. ft. of laboratory capacity.

    The fully refitted space is scheduled for completion in the first quarter and will augment the existing 12,500 sq. ft. site. The development includes office reorganization and will facilitate installation later this year of additional spectroscopic and diffraction equipment.

    Recently, SAFC announced the $12 million expansion of SAFC Pharma's viral product manufacturing facility in Carlsbad, CA. Additionall, the company reported the launch of Pharmorphix services in the U.S. at its flagship manufacturing facility in Madison, WI. This facility will be equipped with new XRPD (X-ray powder diffraction) analytical equipment.

    Other recently announced investments include a $10 million expansion of commercial-scale APIs manufacturing and storage capacity, respectively, at Arklow, Ireland and Buchs, Switzerland, a $29 million potent-fermentation expansion in Jerusalem, Israel, and a high-potent API conjugation suite at its St Louis, MO, manufacturing campus.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...

Unable to get Jobs Listings.

More »

GEN Poll

More » Poll Results »

Biosimilars

Compared to the original biologics, do you think biosimilars run the risks of being less effective and causing more side effects?